Neurology
-
To determine dosing and side effects of dihydroergotamine as they affect outcomes in primary headache disorders. ⋯ Intravenous dihydroergotamine is well-tolerated, and longer treatments produce a better outcome. Nausea is the most common adverse effect, and its control is associated with a better outcome.
-
To investigate the impact of the adjustment of initial intracerebral hemorrhage (ICH) volume by onset-to-imaging time (ultraearly hematoma growth [uHG]) on further hematoma enlargement and outcome in patients with acute ICH. ⋯ The uHG represents a powerful and easy-to-use tool for improving the prediction of HG and outcome in patients with acute ICH.
-
Randomized Controlled Trial Multicenter Study
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
To assess the effects of treatment with onabotulinumtoxinA (Botox, Allergan, Inc., Irvine, CA) on health-related quality of life (HRQoL) and headache impact in adults with chronic migraine (CM). ⋯ This study provides Class 1A evidence that onabotulinumtoxinA treatment reduces headache impact and improves HRQoL.
-
Randomized Controlled Trial Multicenter Study
Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.
To evaluate efficacy and safety of clobazam, a 1,5-benzodiazepine, as adjunctive therapy for Lennox-Gastaut syndrome (LGS). ⋯ This study provides Class II evidence that clobazam as adjunctive therapy is efficacious, in a dosage-dependent manner, in reducing mean weekly drop seizure rates of patients with LGS over 12 weeks.